Table 1 Baseline characteristics at admission (patients) and at baseline (controls). Data presented as median and interquartile range (IQR) for continuous variables and as number (%) for dichotomous variables
Variables | Patients n = 161 | Controls n = 183 | P |
|---|---|---|---|
Clinical characteristics | |||
Age (years) | 63 (57–71) | 65 (57–72) | 0.26 |
Female gender | 47 (29) | 58 (32) | 0.64 |
BMI (kg/m2) | 26 (24–29) | 26 (24–29) | 0.69 |
Current smokers | 56 (35) | 21 (11) | < 0.01 |
Family history of diabetes | 33 (21) | 33 (18) | 0.58 |
Family history of IHD | 85 (53) | 51 (28) | < 0.01 |
Previous medical history | |||
AMI | 33 (21) | 0 (0) | < 0.01 |
Stroke | 6 (4) | 0 (0) | 0.01 |
Congestive heart failure | 13 (8) | 0 (0) | < 0.01 |
Hypertension | 51 (32) | 33 (18) | < 0.01 |
Hyperlipidaemia | 26 (16) | 14 (8) | 0.02 |
Pharmacological treatment* | |||
ACE Inhibitor | 16 (10) | 10 (5) | 0.15 |
Aspirin | 46 (29) | 18 (10) | < 0.01 |
β-Blocker | 56 (35) | 25 (14) | < 0.01 |
Ca2+ blocker | 26 (16) | 8 (4) | < 0.01 |
Thiazide | 10 (6) | 9 (5) | 0.64 |
Furosemide | 15 (9) | 10 (5) | 0.21 |
Statins | 20 (12) | 7 (4) | < 0.01 |
Biochemical characteristics | |||
FPG (mmol/L) | 6.2 (5.6–7.4) | 5.0 (4.6–5.4) | 0.02 |
HbA1c (%) | 4.9 (4.6–5.3) | 4.6 (4.3–5.0) | < 0.01 |
eGFR (ml/min/1.73m2) | 70 (61–82) | N/A | N/A |
CRP2 (mmol/L) | 18 (8–52) | N/A | N/A |
Serum triglycerides^ (mmol/L) | 1.9 (1.5–2.6) | N/A | N/A |
Dysglycaemia¨ | 108 (67) | 64 (35) | < 0.01 |